Testing drug responses using glioblastoma organoids
Patient-derived Organoids As Predictive Models for Drug Response Testing and Repurporsing in Glioblastoma Therapy
This study is testing if lab-grown brain tumor samples from patients can help predict how well different drugs will work for their glioblastoma treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Sex | All |
| Sponsor | Chungnam National University Hospital Academic / other |
| Drugs / interventions | Lazertinib |
| Locations | 1 site (Daejeon, Chungcheongnam-do) |
| Trial ID | NCT06782984 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the prognostic value of patient-derived glioblastoma organoids (GBOs) in predicting responses to conventional and repurposed drugs, including temozolomide, in patients with glioblastoma. The study aims to determine if the drug response observed in patients can be replicated in their corresponding GBOs. Utilizing a drug-response testing platform, the research assesses cell viability and explores the potential application of various chemotherapeutic agents. The goal is to collect diverse genetic information and validate the GBO model as a preclinical alternative to traditional clinical trials.
Who should consider this trial
Good fit: Ideal candidates are patients with primary or recurrent glioblastoma who have undergone standard treatment including surgery and temozolomide-based chemoradiation therapy.
Not a fit: Patients who have not received concurrent chemoradiation therapy or those who refuse participation may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment options for glioblastoma patients.
How similar studies have performed: Previous studies have shown promise in using organoid models for drug sensitivity testing, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * primary or recurrent glioblastoma * patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy * sufficient tumor sample is available for organoid culture Exclusion Criteria: * patients who are not underwent concurrent chemoradiation therapy (CCRT) following surgery * failed to obtain MRI scan after CCRT * patients refusal
Where this trial is running
Daejeon, Chungcheongnam-do
- Chungnam National University Hospital — Daejeon, Chungcheongnam-do, South Korea (Recruiting)
Study contacts
- Principal investigator: Kyung Hwan Kim, MD, PhD — Department of Neurosurgery, Chungnam National University Hospital
- Study coordinator: Kyung Hwan Kim, MD, PhD
- Email: nskhkim@cnuh.co.kr
- Phone: 82-42-280-7367
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.